Merz Aesthetics Marks 15 Years of XEOMIN® With New National Campaign

Merz Aesthetics is commemorating 15 years since the US Food and Drug Administration (FDA) approved XEOMIN® (incobotulinumtoxinA) for aesthetic use, marking a milestone for the company’s flagship neurotoxin in the competitive US injectable market.

Approved for the simultaneous treatment of upper facial lines—including forehead lines, glabellar lines, and lateral canthal lines—XEOMIN® is distinguished by its double-purified formulation and proprietary XTRACT Technology®. The product contains only 3 ingredients and is designed to deliver natural-looking outcomes while minimizing exposure to unnecessary proteins.

To coincide with the anniversary, Merz Aesthetics has introduced a refreshed, multi-channel campaign spanning digital platforms and in-office materials. The initiative emphasizes patient empowerment and encourages individuals to request XEOMIN® specifically, highlighting its established safety and efficacy profile and its positioning as a “naked” neurotoxin without accessory proteins.

According to company data, XEOMIN® has achieved a 96% patient satisfaction rate in clinical studies and has demonstrated consistent safety and efficacy outcomes. In pivotal trials, no patients developed treatment resistance attributed to neutralizing antibodies. Company representatives note that unnecessary proteins in some botulinum toxin formulations may increase the risk of immune response, which can contribute to secondary nonresponse.

“Since its debut, XEOMIN® has been a trusted choice for patients and providers seeking effective, natural-looking results,” said Patrick Urban, President, North America, Merz Aesthetics. “Celebrating 15 years is more than a milestone—it’s a testament to our unwavering commitment to proven performance and advancing aesthetic care.”

Dr. Samantha Kerr, Chief Scientific Officer at Merz Aesthetics, added that the company’s proprietary manufacturing process has helped establish its position in the neurotoxin category, with a continued focus on innovation.

As part of the anniversary celebration, Merz Aesthetics is also launching a sweepstakes through its Xperience+ loyalty program, in which 15 US patients will be eligible to receive a year of complimentary XEOMIN® treatments with participating providers. The promotion runs from February 11 to March 11, 2026, and requires no purchase for entry.